Candel Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Candel Therapeutics şirketinin kazançları yıllık ortalama -19.1% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 40.8% oranında azalan oldu.

Anahtar bilgiler

-19.1%

Kazanç büyüme oranı

6.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-40.8%
Özkaynak getirisi	n/a
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Jul 01

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Apr 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Sep 15

Candel Therapeutics appoints CFO, chief medical officer

Sep 07

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Oct 21

Gelir ve Gider Dağılımı

Candel Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:CADL Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	-52	14	-4
30 Jun 24	-50	14	0
31 Mar 24	-37	14	0
31 Dec 23	-38	14	0
30 Sep 23	-32	14	16
30 Jun 23	-32	15	0
31 Mar 23	-27	15	0
31 Dec 22	-19	15	0
30 Sep 22	-12	16	0
30 Jun 22	-20	15	0
31 Mar 22	-33	13	0
31 Dec 21	-36	11	0
30 Sep 21	-48	10	3
30 Jun 21	-35	8	8
31 Mar 21	-20	7	8
31 Dec 20	-18	6	8
31 Dec 19	-8	3	0

Kaliteli Kazançlar: CADL şu anda kârlı değil.

Büyüyen Kar Marjı: CADL şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CADL kârlı değildir ve zararlar son 5 yılda yılda 19.1% oranında artmıştır.

Büyüme Hızlandırma: CADL 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: CADL kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: CADL 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Candel Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.30 loss in 3Q 2022)

First half 2023 earnings released: US$0.64 loss per share (vs US$0.17 loss in 1H 2022)

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.03 loss in 1Q 2022)

Full year 2022 earnings released: US$0.65 loss per share (vs US$1.91 loss in FY 2021)

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Candel Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

New major risk - Share price stability

Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Candel Therapeutics, Inc. Announces Chief Financial Officer Changes

Candel Therapeutics, Inc. Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.30 loss in 3Q 2022)

New major risk - Share price stability

Candel Therapeutics, Inc. Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Candel Therapeutics, Inc. Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

Price target increased by 8.6% to US$9.50

First half 2023 earnings released: US$0.64 loss per share (vs US$0.17 loss in 1H 2022)

New major risk - Financial position

New major risk - Share price stability

Candel Therapeutics, Inc. Appoints Nicoletta Loggia to the Board of Directors

Candel Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of Can-3110 in Recurrent High-Grade Glioma At the American Society of Gene & Cell Therapy 26Th Annual Meeting

Price target decreased by 17% to US$7.25

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.03 loss in 1Q 2022)

Full year 2022 earnings released: US$0.65 loss per share (vs US$1.91 loss in FY 2021)

Independent Director recently bought US$73k worth of stock

Consensus forecasts updated

Price target decreased to US$11.60

Candel Therapeutics, Inc. R&D Day Presentations Spotlight Its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

Candel Therapeutics Announces Oral Presentation of Updated Data from Its Phase 1 Clinical Trial of Can-3110 in 41 Patients with Recurrent High-Grade Glioma At the Society for Neuro-Oncology 27Th Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics Announces Jason A. Amello as Chief Financial Officer, Effective September 21, 2022

Candel Therapeutics appoints CFO, chief medical officer

Candel Therapeutics, Inc., Annual General Meeting, Oct 13, 2022

Consensus forecasts updated

Consensus forecasts updated

Less than half of directors are independent

First half 2022 earnings released

Candel Therapeutics, Inc. Announces Executive Changes

Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index

Candel Therapeutics, Inc. Releases Initial Data on CAN-2409 in A Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Candel Therapeutics, Inc Expects to Present Initial Data from an Ongoing Phase 2 Clinical Trial of CAN-2409

Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer

Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer

Candel Therapeutics, Inc. Appoints Dr. Francesca Barone as Chief Scientific Officer

Candel Therapeutics, Inc. Removes Estuardo Aguilar-Cordova and Laura Aguilar from the Board

Candel Therapeutics, Inc. and Partnership for Accelerating Cancer Therapies to Collaborate on Lung Cancer Trial for CAN-2409

Third quarter 2021 earnings released: US$0.69 loss per share

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Chairman recently bought US$411k worth of stock

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin